Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 96 clinical trials
featured
PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.

PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2

endocrine therapy
erbb2
HER2
breast cancer
hormone therapy
  • 220 views
  • 24 Nov, 2020
  • 1 location
featured
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of Subjects with Advanced Renal Cell Carcinoma

A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of

  • 220 views
  • 25 Mar, 2021
  • 1 location
featured
  • 120 views
  • 25 Mar, 2021
  • 1 location
featured
ABSORB III - Randomized Controlled Trial

ABSORB III - Randomized Controlled Trial

  • 230 views
  • 08 Nov, 2020
  • 1 location
Itacitinib + Everolimus in Hodgkin Lymphoma

This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).

gonadotropin
carcinoma
everolimus
neutrophil count
gilbert's syndrome
  • 1 views
  • 01 Aug, 2021
  • 1 location
Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus

The purpose of this study is to address the pharmacokinetic (PK) profiles of everolimus and tacrolimus in combination in de novo kidney transplant recipients, comparing 1.5 and 3 mg per

tacrolimus
kidney transplant
  • 13 views
  • 07 Nov, 2020
  • 1 location
Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer

This is an open-label, mono-center phase I/II study designed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of RAD001 in combination with carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer. Additionally, the study is designed to characterize the safety, the tolerability and efficacy of …

carboplatin
anthracyclines
taxane
stage iv breast cancer
  • 22 views
  • 07 Nov, 2020
  • 1 location
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or

  • 13 views
  • 04 Aug, 2021
  • 10 locations
Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion

This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose. The primary goal is to assess the change in renal function at 6 and 12 …

tacrolimus
kidney biopsy
immunosuppressive agents
renal impairment
  • 11 views
  • 07 Nov, 2020
  • 1 location
Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is

  • 14 views
  • 07 Nov, 2020
  • 1 location